Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT01013818 is registered in ClinicalTrials.gov with Human Genome Sciences Inc. as lead sponsor.

NCT NCT01013818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01013818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Lead sponsor
Human Genome Sciences Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2009
Completion date
October 31, 2011
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoid malignancies